News
Incyte's JAK inhibitor for GVHD fails phase 3 trial
Incyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another setback for a company in need of more drug successes.
Friday 9 October 2026
